Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 22761-22770 Newer>

The Motley Fool April 30, 2007 Rick Aristotle Munarriz	PAR Us, Hilton The hotelier's strong report proves that inns are in. Investors, take note.
The Motley Fool April 30, 2007 Dave Mock	Verizon Hits the Accelerator Investors awoke to good news from Verizon Communications this morning as the company reported a solid quarter of accelerating growth in key business areas.
The Motley Fool April 30, 2007 Dan Bloom	Can Anadigics Deliver? Despite a forecast for slowing growth, the long-term outlook for the small semiconductor company looks bright. Investors, take note.
The Motley Fool April 30, 2007 Anders Bylund	Foolish Forecast: TTM Will Come Back The quick-release circuit board manufacturer is set to report its most recently quarterly report. Investors, take note.
The Motley Fool April 30, 2007 Rich Duprey	Coventry's Healthy Beat The health insurer manages to grow through acquisitions and expanding membership rolls. Its stock is trading at around 13 times 2008 earnings, putting the company in the middle of the competition.
The Motley Fool April 30, 2007 David Lee Smith	Can You Dig It, Exxon? ExxonMobil is the operator on the world's longest measured depth extended-reach well. But what does it mean for investors?
The Motley Fool April 30, 2007 Tom Taulli	Datalink Reboots The data-storage consultant loses its footing with its latest acquisition. Shareholders waiting for improvement may have to remain patient.
The Motley Fool April 30, 2007 Emil Lee	How Deep Is Your Moat? It's vital to be versed in the competitive advantage of the companies in which you invest.
The Motley Fool April 30, 2007 Jack Uldrich	Again, No News Is Good News Don't try to compete with the big boys on short-term market news. With new tools such as Reuters' software program, it is clear institutional investors have an upper hand.
The Motley Fool April 30, 2007 Mike Havrilla	ThermoGenesis Is Ready to Heat Up Shares of ThermoGenesis are currently trading at compelling levels that could produce nice gains if the company receives FDA approvals and subsequently ramps up the sales of its umbilical cord blood stem cell processing machines and ancillary products.
<Older 22761-22770 Newer> Return to current articles.